The chairman of Cambridge Therapeutics, John Klein has facilitated FDA approval of more than 300 generic drugs throughout his extensive career in the pharmaceutical industry. John Klein is also the chairman and CEO of Bilogix, LLC, in Alpine, NJ.
Bilogix is an enterprise performance management (EPM) firm, meaning that it offers proprietary services designed to boost business clients’ operational performance and overall efficiency with an emphasis on information-technology infrastructure. EPM processes help measure, analyze, and estimate organizational performance and add value to businesses by directing the appropriate resources to achieve desired objectives. While EPM shares some commonalities with data processing tools like analytics and business intelligence (BI), they differ in their approach.
Most notably, BI and analytics tools focus on highlighting relevant information pertaining to daily operations so leaders can make informed decisions. In this way, they are generally reactive. Conversely, EPM tools are proactive. This is because they allow organizations to assess overall performance and make necessary changes based on information and data as it becomes available. Both BI and EPM have their benefits, and companies are increasingly leveraging both to track and refine operations.
Serving as the chairman of Cambridge Therapeutics in Alpine, NJ, John Klein has more than 20 years of experience in pharmaceutical manufacturing. In addition to leading Cambridge Therapeutics, John Klein functions as the chairman and CEO of Bilogix, an enterprise performance management (EPM) firm.
With a focus on helping business clients achieve maximum organizational efficiency and increase profits, Bilogix offers comprehensive analysis of operational data, as well as customized insights on improving business management. In today’s competitive business environment, EPM software and consulting services are considered necessary for organizations that want to boost their digital capabilities and remain profitable.
EPM analysis links financial data with performance metrics, which often reveals new strategies for generating revenue, as well as other steps for streamlining operations and cutting unnecessary costs. EPM solutions can also help managers and executives become more savvy as they use digital tools to monitor financial performance in real time and identify sales trends. Organizations of all types can benefit from an EPM solution in order to better understand their enterprise’s financial data and make more informed business decisions.
An experienced pharmaceutical executive based in Alpine, NJ, John Klein is the chairman of Cambridge Therapeutics. Credited with obtaining US Food and Drug Administration approval for over 300 generic drugs, John Klein remains up to date on health-related developments in NJ.
A new program based in Paterson, NJ, aims to improve health outcomes by offering affordable housing to people in need. In collaboration with the state, St. Joseph’s Health will provide increased aid to frequent visitors to its emergency departments by helping to transform a nearby parking lot into a first-of-its-kind affordable-housing development. The property site is located across the street from St. Joseph’s University Medical Center. When finished, it will have 70 residential units that include one- to three-bedroom apartments. Residents will be eligible for housing vouchers to subsidize their rent. The venture is part of the Hospital Housing Partnership Program, which will establish a support system to low-income individuals.
While most of the financing comes from St. Joseph’s, the Housing and Mortgage Finance Agency will provide $12 million in funding, and the New Jersey Development Corporation will manage the construction at the site. As of July 2019, eight other hospitals expressed interest in joining the Hospital Housing Partnership Program.
New Jersey-based executive John Klein serves as the chairman of Cambridge Therapeutics. In addition to overseeing operations at Cambridge Therapeutics, John Klein takes an active interest in developments concerning health care and health policy.
New Jersey officials announced new rules intended to expand access to the state’s medical marijuana program, following the directive set in an executive order by Governor Phil Murphy. In addition to removing bureaucratic hurdles for young patients, the new policies will allow patients with a wider variety of diseases and ailments to access medical marijuana.
Taking effect May 20, 2019, the reforms also relax some of the regulations governing businesses that grow, produce, and sell medicinal cannabis. Other policies already in effect but now codified include reducing medical cannabis costs for patients and permitting doctors to prescribe medical marijuana without being named publicly as a physician participating in the program.
An accomplished pharmaceutical executive, John Klein leads New Jersey-based Cambridge Therapeutics as chairman. Aside from steering the development of Cambridge Therapeutics, John Klein maintains an active interest in following health-related developments impacting residents of New Jersey and beyond.
New Jersey Governor Phil Murphy recently signed a package of bills aimed at reducing the state’s extremely high maternal mortality rate. In particular, the bills aim to address racial disparities in health care: throughout the nation, African American mothers are more than four times more likely than white women to die of complications related to pregnancy, childbirth, or postpartum recovery. “In a state that is among the very wealthiest in our nation,” said Governor Murphy, “these disparities stand in stark contrast to our core values.”
The bill signings occurred one day after the Centers for Disease Control and Prevention released a report concluding that nearly half of pregnancy-related deaths are preventable. One provision in the newly signed New Jersey bills requires Medicaid to cover doula services, a birth support role that has been shown to improve birth outcomes. Another provision discourages the scheduling of cesarean sections before the baby is full term out of convenience rather than necessity.
Cambridge Therapeutics founder and chairman John Klein directs the innovative work of a Teaneck, New Jersey-based team dedicated to producing next-generation medical devices and health care products. Outside of his pursuits with Cambridge Therapeutics, he supports nonprofit organizations focused on health care, education, and the public good. John Klein also serves as a trustee with Hackensack Meridian Health Hospitals, a network that consistently receives high rankings for its quality of care.
In 2018, the local news outlet NJ.com amplified a report analyzing the safety of hospitals nationwide and noting how the medical facilities in New Jersey had ranked. The NJ.com article’s lead noted the good news that New Jersey’s hospitals as a group earned more top ratings for safety than the hospitals of any other state.
Thirty-eight of the 67 New Jersey hospitals surveyed – including eight facilities in the HMH network – received a grade of “A.”
Produced under the branding of the Leapfrog Hospital Safety Grade organization, the report was six years in the making, as an expert panel evaluated hospitals in terms of their ability to keep patients secure from infections, injuries, and staff errors.
Among the other recent accolades that HMH has received is a 2018-19 U.S. News & World Report ranking as one of the state’s two best hospitals overall.
John Klein functions as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. In addition to his pursuits with Cambridge Therapeutics, John Klein serves as a member of the Board of Trustees of Hackensack Meridian Health Hospitals and keeps apprised of developments in the state of health care in his region through various news outlets.
In April 2019, NJSpotlight’s online “Healthcare” section summarized a major new report on the health care landscape in New Jersey that additionally offered insights into the best ways for the state’s policymakers to improve the quality and equitable delivery of medical care.
Entitled “Building a Culture of Health,” this report was created with support from the Robert Wood Johnson Foundation and Rutgers University.
It notes that, despite New Jersey’s advances in providing strong family leave programs for workers, high-quality early childhood education, and public education campaigns that have helped reduce smoking rates, a disturbing number of disparities in health care distribution remain across ethnicity, income, geography, and social class. The report estimates that close to 6,500 people die needlessly in the state every year due to such barriers to access.
The report consists of more than one dozen specific recommendations to officials planning health care policy, urging them to fund targeted improvements. The first item on the list involves upgrading the quality of maternal and infant care. Others given high priority include strengthening overall community health by ensuring that at-risk families can access quality housing, education, and paid family leave benefits.
With more than three decades of experience as a healthcare and pharmaceutical executive, John Klein functions as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. During his six-year service as the CEO of Cambridge Therapeutics, John Klein developed knowledge of the Food and Drug Administration’s Code of Federal Regulations, as well as rules enacted by the State of New Jersey.
The New Jersey Department of Human Services (NJDHS) continues to make changes to state policy to ensure Medicaid patients have access to effective therapies for substance-abuse disorders. As of March 31, 2019, the state’s 1.7 million Medicaid enrollees are no longer required to gain approval from the managed-care plan that administers their insurance benefits before receiving medication-assisted treatment (MAT) for opiate addiction.
Viewed as the gold-standard for addressing opiate dependency, MAT involves prescribing patients opioid-replacement medications to minimize withdrawal symptoms and help calm addictive behaviors. In addition to assisting to eliminate insurance hurdles for state Medicaid enrollees, the NJDHS released new rules mandating all addiction-treatment facilities with such patients to offer MAT as a treatment option, effective July 1, 2019.
A distinguished pharmaceutical executive, John Klein serves as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. Also the former CEO of Cambridge Therapeutics, John Klein keeps up with healthcare industry news in his state.
In April 2019, New Jersey health officials released a statement recommending a large increase in the number of medical-marijuana dispensaries to meet the state’s rapidly-expanding demand. Currently, New Jersey has only six dispensaries, called Alternative Treatment Centers, but health officials estimate the state will need to grow its capacity to 50 to 90 dispensaries over three years to keep pace with the rising number of people using medicinal marijuana.
With approximately 100 new medical-marijuana patients per day, the mounting demand is partly driven by Governor Phil Murphy’s recent move to approve new conditions for treatment with medical marijuana, including chronic pain, end-stage cancer, post-traumatic stress disorder, and opioid use disorder. The number of physicians prescribing through the state’s medicinal-marijuana program also has grown by about 40 percent since January 2018, when Governor Murphy took office.
Drawing on his extensive background in the healthcare and pharmaceutical industries, John Klein serves as the chairman of Cambridge Therapeutics. Aside from providing strategic direction to Cambridge Therapeutics, John Klein serves as a trustee for New Jersey’s Hackensack Meridian Health network.
New Jersey officials recently have undertaken several initiatives to improve mental health care in the state. For instance, Hackensack Meridian Health, a network of 16 hospitals and hundreds of outpatient physician offices, has formed a new partnership with Carrier Clinic, a long-standing addiction-treatment agency, to provide integrated behavioral healthcare for its patients.
In addition, the state is working to make it easier for children with emotional and behavioral issues to receive appropriate health care. New Jersey has developed nine regional hospital-based programs that connect pediatricians with behavioral-health providers for advice on diagnoses and treatment. With new funding from the U.S. Department of Health and Human Services and The Nicholson Foundation, the state plans to invest an additional $2.3 million into programs that integrate pediatric behavioral health.